IGF1R blockade with ganitumab results in systemic effects on the GH-IGF axis in mice

Journal of Endocrinology

Volumn 221, Issue 1, 2014, Pages 145-155

  Moody, Gordon ^a   Beltran, Pedro J ^a   Mitchell, Petia ^a   Cajulis, Elaina ^a   Chung, Young Ah ^a   Hwang, David ^b   Kendall, Richard ^a   Radinsky, Robert ^a   Cohen, Pinchas ^c   Calzone, Frank J ^a  

^a AMGEN INC   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Ganitumab; Human; IGF1R; IGFBP3; Murine; Receptor pituitary

Indexed keywords

CD11B ANTIGEN; FLUOROURACIL; GANITUMAB; GROWTH HORMONE; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOPHOSPHORYLATION; BINDING ASSAY; CANCER INHIBITION; CARCINOMA CELL; COLON CARCINOMA; CONTROLLED STUDY; CROSS REACTION; DRUG EFFICACY; FEMALE; FLOW CYTOMETRY; GENETIC ANALYSIS; GLUCOSE METABOLISM; GLUCOSE TOLERANCE; GLUCOSE TOLERANCE TEST; GLUCOSE TRANSPORT; GROWTH HORMONE BLOOD LEVEL; GROWTH HORMONE RELEASE; HOMEOSTASIS; HYPOPHYSIS FUNCTION; IMPAIRED GLUCOSE TOLERANCE; MALE; MOUSE; NEGATIVE FEEDBACK; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; TUMOR VOLUME; WEIGHT GAIN;

GANITUMAB; HUMAN; IGF1R; IGFBP3; MURINE; RECEPTOR PITUITARY;

ANIMALS; ANTIBODIES, MONOCLONAL; FEMALE; GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR I; INSULIN-LIKE GROWTH FACTOR II; KINETICS; LUNG; MALE; MICE; MICE, NUDE; PHOSPHORYLATION; RECEPTOR, IGF TYPE 1; SIGNAL TRANSDUCTION;

EID: 84897898210     PISSN: 00220795     EISSN: 14796805     Source Type: Journal    
DOI: 10.1530/JOE-13-0306     Document Type: Article

References (36)

1. Anzo M, Cobb LJ, Hwang DL, Mehta H, Said JW, Yakar S, LeRoith D & Cohen P 2008 Targeted deletion of hepatic Igf1 in TRAMP mice leads to dramatic alterations in the circulating insulin-like growth factor axisbut does not reduce tumor progression. Cancer Research 68 3342-3349.
2. Baker J, Liu JP, Robertson EJ & Efstratiadis A 1993 Role of insulin-like growth factors in embryonic and postnatal growth. Cell 75 73-82.
3. Baserga R, Hongo A, Rubini M, Prisco M & Valentinis B 1997 The IGF-I receptor in cell growth, transformation and apoptosis. Biochimica et Biophysica Acta 1332 F105-F126.
4. Bass J, Kurose T, Pashmforoush M & Steiner DF 1996 Fusion of insulin receptor ectodomains to immunoglobulin constant domains reproduces high-affinity insulin binding in vitro. Journal of Biological Chemistry 271 19367-19375.
5. Beltran PJ, Mitchell P, Chung YA, Cajulis E, Lu J, Belmontes B, Ho J, TsaiMM, Zhu M, Vonderfecht S et al. 2009 AMG 479, a fully human anti-insulin-like growth factor receptor type I monoclonal antibody, inhibits the growth and survival of pancreatic carcinoma cells. Molecular Cancer Therapeutics 8 1095-1105.
6. Beltran PJ, Chung YA, Moody G, Mitchell P, Cajulis E, Vonderfecht S, Kendall R, Radinsky R & Calzone FJ 2011 Efficacy of ganitumab (AMG 479), alone and in combination with rapamycin, in Ewing's and osteogenic sarcoma models. Journal of Pharmacology and Experimental Therapeutics 337 644-654.
7. Burtrum D, Zhu Z, Lu D, Anderson DM, Prewett M, Pereira DS, Bassi R, Abdullah R, Hooper AT, Koo H et al. 2003 A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks liganddependent signaling and inhibits human tumor growth in vivo. Cancer Research 63 8912-8921.
8. Calzone FJ, Cajulis E, Chung YA, Tsai MM, Mitchell P, Lu J, Chen C, Sun J, Radinsky R, Kendall R et al. 2013 Epitope-specific mechanisms of IGF1R inhibition by ganitumab. PLoS ONE 8 e55135.
9. Cohen BD, Baker DA, Soderstrom C, Tkalcevic G, Rossi AM, Miller PE, Tengowski MW, Wang F, Gualberto A, Beebe JS et al. 2005 Combination therapy enhances the inhibition of tumor growth with the fully human anti-type 1 insulin-like growth factor receptor monoclonal antibody CP-751,871. Clinical Cancer Research 11 2063-2073.
10. Frasca F, Pandini G, Scalia P, Sciacca L, Mineo R, Costantino A, Goldfine ID, Belfiore A & Vigneri R 1999 Insulin receptor isoform A, a newly recognized, high-affinity insulin-like growth factor II receptor in fetal and cancer cells. Molecular and Cellular Biology 19 3278-3288. Gallagher EJ & LeRoith D 2011 Minireview: IGF, insulin, and cancer. Endocrinology 152 2546-2551.
11. Gallagher EJ & LeRoith D 2011 Minireview: IGF, insulin, and cancer. Endocrinology 152 2546-2551.
12. Guha M 2013 Anticancer IGF1R classes take more knocks. Nature Reviews. Drug Discovery 12 250.
13. Heidegger I, Pircher A, Klocker H & Massoner P 2011 Targeting the insulinlike growth factor network in cancer therapy. Cancer Biology & Therapy 11 701-707.
14. Holzenberger M, Dupont J, Ducos B, Leneuve P, Geloen A, Even PC, Cervera P & Le Bouc Y 2003 IGF-1 receptor regulates lifespan and resistance to oxidative stress in mice. Nature 421 182-187.
15. Hwang DL, Lee PD & Cohen P 2008 Quantitative ontogeny of murine insulin-like growth factor (IGF)-I, IGF-binding protein-3 and the IGF-related acid-labile subunit. Growth Hormone & IGF Research 18 65-74.
16. Kulkarni RN 2002 Receptors for insulin and insulin-like growth factor-1 and insulin receptor substrate-1 mediate pathways that regulate islet function. Biochemical Society Transactions 30 317-322.
17. Kull FC Jr, Jacobs S, Su YF, Svoboda ME, Van Wyk JJ & Cuatrecasas P 1983 Monoclonal antibodies to receptors for insulin and somatomedin-C. Journal of Biological Chemistry 258 6561-6566.
18. Lee C, Safdie FM, Raffaghello L, Wei M, Madia F, Parrella E, Hwang D, Cohen P, Bianchi G & Longo VD 2010 Reduced levels of IGF-I mediate differential protection of normal and cancer cells in response to fasting and improve chemotherapeutic index. Cancer Research 70 1564-1572.
19. Le Roith D, Scavo L & Butler A 2001 What is the role of circulating IGF-I? Trends in Endocrinology and Metabolism 12 48-52. (doi:10.1016/ S1043-2760(00)00349-0)
20. Li SL, Kato J, Paz IB, Kasuya J & Fujita-Yamaguchi Y 1993 Two new monoclonal antibodies against the alpha subunit of the human insulin-like growth factor-I receptor. Biochemical and Biophysical Research Communications 196 92-98.
21. Liu JL & LeRoith D 1999 Insulin-like growth factor I is essential for postnatal growth in response to growth hormone. Endocrinology 140 5178-5184.
22. Maloney EK, McLaughlin JL, Dagdigian NE, Garrett LM, Connors KM, Zhou XM, Blattler WA, Chittenden T & Singh R 2003 An antiinsulin- like growth factor I receptor antibody that is a potent inhibitor of cancer cell proliferation. Cancer Research 63 5073-5083.
23. Naranjo WM, Yakar S, Sanchez-Gomez M, Perez AU, Setser J & LeRoith D 2002 Protein calorie restriction affects nonhepatic IGF-I production and the lymphoid system: studies using the liver-specific IGF-I gene-deleted mouse model. Endocrinology 143 2233-2241.
24. Pandini G, Frasca F, Mineo R, Sciacca L, Vigneri R & Belfiore A 2002 Insulin/insulin-like growth factor I hybrid receptors have different biological characteristics depending on the insulin receptor isoform involved. Journal of Biological Chemistry 277 39684-39695.
25. Pollak M 2012 The insulin and insulin-like growth factor receptor family in neoplasia: an update. Nature Reviews. Cancer 12 159-169.
26. Rodon J, DeSantos V, Ferry RJ Jr & Kurzrock R 2008 Early drug development of inhibitors of the insulin-like growth factor-I receptor pathway: lessons from the first clinical trials. Molecular Cancer Therapeutics 7 2575-2588.
27. Sjogren K, Liu JL, Blad K, Skrtic S, Vidal O, Wallenius V, LeRoith D, Tornell J, Isaksson OG, Jansson JO et al. 1999 Liver-derived insulin-like growth factor I (IGF-I) is the principal source of IGF-I in blood but is not required for postnatal body growth in mice. PNAS 96 7088-7092.
28. Soos MA, Field CE, Lammers R, Ullrich A, Zhang B, Roth RA, Andersen AS, Kjeldsen T & Siddle K 1992 A panel of monoclonal antibodies for the type I insulin-like growth factor receptor. Epitope mapping, effects on ligand binding, and biological activity. Journal of Biological Chemistry 267 12955-12963.
29. Tap WD, Demetri G, Barnette P, Desai J, Kavan P, Tozer R, Benedetto PW, Friberg G, Deng H,McCaffery I et al. 2012 Phase II study of ganitumab, a fully human anti-type-1 insulin-like growth factor receptor antibody, in patients with metastatic ewing family tumors or desmoplastic small round cell tumors. Journal of Clinical Oncology 30 1849-1856.
30. Valentinis B, Navarro M, Zanocco-Marani T, Edmonds P, McCormick J, Morrione A, Sacchi A, Romano G, Reiss K & Baserga R 2000 Insulin receptor substrate-1, p70S6K, and cell size in transformation and differentiation of hemopoietic cells. Journal of Biological Chemistry 275 25451-25459.
31. Welniak LA, Karas M, Yakar S, Anver MR, Murphy WJ & LeRoith D 2004 Effects of organ-specific loss of insulin-like growth factor-I production on murine hematopoiesis. Biology of Blood and Marrow Transplantation 10 32-39.
32. Xiong L, Kasuya J, Li SL, Kato J & Fujita-Yamaguchi Y 1992 Growthstimulatory monoclonal antibodies against human insulin-like growth factor I receptor. PNAS 89 5356-5360.
33. Yakar S, Liu JL, Stannard B, Butler A, Accili D, Sauer B & LeRoith D 1999 Normal growth and development in the absence of hepatic insulin-like growth factor I. PNAS 96 7324-7329.
34. Yakar S, Liu JL, Fernandez AM, Wu Y, Schally AV, Frystyk J, Chernausek SD, Mejia W & Le Roith D 2001 Liver-specific igf-1 gene deletion leads to muscle insulin insensitivity. Diabetes 50 1110-1118.
35. Yakar S, Pennisi P, Kim CH, Zhao H, Toyoshima Y, Gavrilova O & LeRoith D 2005 Studies involving the GH-IGF axis: lessons from IGF-I and IGF-I receptor gene targeting mouse models. Journal of Endocrinological Investigation 28(Suppl 5) 19-22.
36. Yuen JS & Macaulay VM 2008 Targeting the type 1 insulin-like growth factor receptor as a treatment for cancer. Expert Opinion on Therapeutic Targets 12 589-603.